Vaccine against Dengue
Conditions
Interventions
Observational Open-label study, Case-control study with negative test. In the healthcare units within the study area, suspected dengue cases confirmed through laboratory testing will be considered as
Sponsors
Secretaria Municipal de Saúde do Rio de Janeiro
Secretaria Municipal de Saúde do Rio de Janeiro
Eligibility
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: Individuals of both genders; aged 18 to 59 years; residing in the Administrative Region (RA) of Guaratiba in the Programatic area (AP) 5.2 of the city during the inclusion period; Who agree to participate in the research
Exclusion criteria
Exclusion criteria: Individuals with immunosuppression; pregnant or lactating individuals; participants who have received any blood product in the last 3 months or have had a hypersensitivity reaction to any component of the vaccine; participants who have previously received any dengue vaccine; individuals with an acute febrile illness, or those who have received another live virus vaccine in the last four weeks will have their inclusion postponed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effectiveness of the vaccine in preventing symptomatic cases and hospitalizations due to any serotype of Dengue | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the incidence of symptomatic cases and hospitalizations due to Dengue between vaccinated and non-vaccinated individuals, providing a relative measure of the vaccine's efficacy in preventing these events | — |
Countries
Brazil
Contacts
Public ContactSergio Assis
Instituto Nacional de Infectologia - INI / Fiocruz
Outcome results
None listed